Robert Leonardi, MD
Interventional Cardiology · West Columbia, SCNPI 1013182898
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $126,094 of the $203,329 with a category attached, or 62.0%. Edwards Lifesciences accounts for 65.6% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2021 at $63,388 and has fallen 73.6% since, to $16,727 in 2025. Among interventional cardiology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 582 payments — averaging $349.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$133K
- Inari Medical, Inc.$41K
- Boston Scientific$17K
- Abbott$6K
- Medtronic$1K
- Novartis$931
- plus $3K from 30 others
Across 219 payments — averaging $3094.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$488K
- Abbott$153K
- Inari Medical, Inc.$31K
- Medtronic$7K
What the payments were for
- Consulting fees$126,09462%
- Speaking & faculty fees$29,09414%
- Grants$890%
- Travel & lodging$34,45117%
- Food & beverage$13,5767%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 130 | $133,351 |
| Inari Medical, Inc. | 54 | $41,368 |
| Boston Scientific | 109 | $17,417 |
| Abbott | 83 | $6,423 |
| Medtronic(2 entities) | 34 | $1,167 |
| Novartis | 67 | $931 |
| Abiomed | 8 | $713 |
| W. L. Gore & Associates, Inc. | 3 | $249 |
| Cardiva Medical, Inc. | 7 | $183 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $168 |
| Stryker | 6 | $148 |
| Amgen | 9 | $139 |
| AstraZeneca | 9 | $116 |
| Chiesi USA, Inc. | 6 | $108 |
| Atricure, Inc. | 6 | $105 |
| Shockwave Medical, Inc | 3 | $96 |
| E.r. Squibb & Sons, L.L.C. | 3 | $65 |
| Alnylam Pharmaceuticals Inc. | 2 | $53 |
| Biosense Webster, Inc. | 2 | $45 |
| Novo Nordisk | 2 | $42 |
| Johnson & Johnson | 3 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Angiodynamics, Inc. | 2 | $41 |
| Arbor Pharmaceuticals, Inc. | 3 | $39 |
| Cardiovascular Systems Inc. | 3 | $39 |
| Cordis US CORP. | 2 | $36 |
| Philips North America LLC | 2 | $35 |
| Merck | 2 | $25 |
| Pfizer | 2 | $24 |
| Biotronik Inc. | 2 | $24 |
| Bard Peripheral Vascular, Inc. | 1 | $22 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Impulse Dynamics (USA) Inc. | 1 | $16 |
| EKOS Corporation | 1 | $14 |
| KCI USA, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$130,500
- CT THROMBECTOMY SYSTEM KIT$54,274
- FLOWTRIEVER CATHETER, S$27,479
- GENERAL - STRUCTURAL HEART$8,306
- GENERAL - THERAPIES$4,865
- MitraClip$2,206
- LOTUS EDGE$1,356
- AMPLATZER Occluders$624
- Mitra Clip system$490
- AVVIGO Guidance System$446
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$354
- SAPIEN 3 Ultra RESILIA$281
- RESOLUTION CLIP$246
- MitraClip System$228
- Ultreon$204
- GORE CARDIOFORM Septal Occluder$178
- PASCAL$165
- COREVALVE EVOLUT R$161
- Baylis Medical Company Radiofrequency Puncture Generator$140
- FlowTriever$128
How this compares
$203,329 in reported general payments places this provider in the 95th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 402 | $371,482 |
| EntrestoSacubitril/Valsartan | 105 | $91,840 |
| BrilintaTicagrelor | 105 | $53,596 |
| XareltoRivaroxaban | 33 | $39,250 |
| MultaqDronedarone Hcl | 11 | $24,041 |
| JardianceEmpagliflozin | 14 | $13,348 |
| FarxigaDapagliflozin Propanediol | 11 | $6,172 |
| Metoprolol Succinate | 323 | $4,465 |
| Dofetilide | 19 | $4,451 |
| Atorvastatin Calcium | 310 | $3,676 |
| Ranolazine ErRanolazine | 21 | $3,375 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 86 | $3,108 |
| Losartan Potassium | 253 | $2,995 |
| Carvedilol | 363 | $2,896 |
| Ezetimibe | 61 | $2,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $24 | $371,482402 claims |
| NovartisEntresto | $931 | $91,840105 claims |
| AstraZenecaBrilinta, Farxiga | $116 | $59,768116 claims |
| Johnson & JohnsonXarelto | $42 | $39,25033 claims |
| Sanofi-aventis U.S. LLCMultaq | $41 | $24,04111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in West Columbia
- Christopher PerryWest Columbia$26K
- Robert MalanukWest Columbia$25K
- Gregory GiuglianoWest Columbia$25K
- Garrett RuthWest Columbia$14K
- Jonathan HewettWest Columbia$11K
- Brandon DraftsWest Columbia$11K
- William BrearleyWest Columbia$10K
- Brian WallWest Columbia$10K
- Daniel SteinbergCharleston$611K
- Brian BrownSpartanburg$389K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.